中程度から重度の尋常性乾癬患者を対象としたORKA-001の用量設定試験 (EVERLAST-B)
中等症から重症の尋常性乾癬を有する参加者を対象とした、ORKA-001の多施設共同、無作為化、二重盲検、プラセボ対照、用量範囲設定試験
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.
調査の概要
詳細な説明
This is a multicenter, randomized, double-blinded, placebo-controlled, dose ranging study designed to identify the optimal induction dosing regimen of ORKA-001 in approximately 160 adult participants with moderate-to-severe plaque psoriasis.
The study will evaluate the efficacy and safety of 3 induction dosing regimens of ORKA-001 compared to placebo and will include 3 maintenance regimens.
The study will consist of 4 periods:
- Screening Period of up to 6 weeks
- Induction Period of up to 28 weeks (Day 1 [Baseline] to Week 28)
- Maintenance Period of up to approximately 72 weeks (Week 28 to Week 100)
- Post-treatment Follow-up Period: Participants will have the option to enter the open-label extension (OLE) study. Participants who opt out of the OLE study and/or withdraw from the study must be followed for 48 weeks after the End of Treatment (EOT)/Early Termination (ET) visit.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85032
- Oruka Therapeutics Investigative Site
-
-
Arkansas
-
North Little Rock、Arkansas、アメリカ、72117
- Oruka Therapeutics Investigative Site
-
-
California
-
Los Angeles、California、アメリカ、90045
- Oruka Therapeutics Investigative Site
-
Los Angeles、California、アメリカ、90024
- Oruka Therapeutics Investigative Site
-
San Diego、California、アメリカ、92123
- Oruka Therapeutics Investigative Site
-
-
Florida
-
Miami、Florida、アメリカ、33126
- Oruka Therapeutics Investigative Site
-
-
Illinois
-
Rolling Meadows、Illinois、アメリカ、60008
- Oruka Therapeutics Investigative Site
-
-
Indiana
-
Plainfield、Indiana、アメリカ、46168
- Oruka Therapeutics Investigative Site
-
-
Maryland
-
Rockville、Maryland、アメリカ、20850
- Oruka Therapeutics Investigative Site
-
-
New York
-
Kew Gardens、New York、アメリカ、11415
- Oruka Therapeutics Investigative Site
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27516
- Oruka Therapeutics Investigative Site
-
-
Ohio
-
Cleveland、Ohio、アメリカ、44106
- Oruka Therapeutics Investigative Site
-
Mason、Ohio、アメリカ、45040
- Oruka Therapeutics Investigative Site
-
-
Oregon
-
Portland、Oregon、アメリカ、97201
- Oruka Therapeutics Investigative Site
-
Portland、Oregon、アメリカ、97210
- Oruka Therapeutics Investigative Site
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104
- Oruka Therapeutics Investigative Site
-
-
Texas
-
Frisco、Texas、アメリカ、75033
- Oruka Therapeutics Investigative Site
-
Houston、Texas、アメリカ、77004
- Oruka Therapeutics Investigative Site
-
Webster、Texas、アメリカ、77598
- Oruka Therapeutics Investigative Site
-
-
Virginia
-
Norfolk、Virginia、アメリカ、23502
- Oruka Therapeutics Investigative Site
-
-
-
-
British Columbia
-
Surrey、British Columbia、カナダ、V3R 6A7
- Oruka Therapeutics Investigative Site
-
Surrey、British Columbia、カナダ、V3V 0C6
- Oruka Therapeutics Investigative Site
-
-
New Brunswick
-
Fredericton、New Brunswick、カナダ、E3B 1G9
- Oruka Therapeutics Investigative Site
-
-
Ontario
-
Ajax、Ontario、カナダ、L1S 7K8
- Oruka Therapeutics Investigative Site
-
Markham、Ontario、カナダ、L3P 1X3
- Oruka Therapeutics Investigative Site
-
Peterborough、Ontario、カナダ、K9J 5K2
- Oruka Therapeutics Investigative Site
-
-
Quebec
-
Montreal、Quebec、カナダ、HZX 2V1
- Oruka Therapeutics Investigative Site
-
Québec、Quebec、カナダ、G1V 4X7
- Oruka Therapeutics Investigative Site
-
-
-
-
Barcelona
-
Badalona、Barcelona、スペイン、08916
- Oruka Therapeutics Investigative Site
-
Barcelona、Barcelona、スペイン、08041
- Oruka Therapeutics Investigative Site
-
-
Madrid
-
Madrid、Madrid、スペイン、28002
- Oruka Therapeutics Investigative Site
-
Madrid、Madrid、スペイン、28046
- Oruka Therapeutics Investigative Site
-
-
-
-
Baden-Wuerrtemberg
-
Heidelberg、Baden-Wuerrtemberg、ドイツ、69120
- Oruka Therapeutics Investigative Site
-
-
Hesse
-
Frankfurt am Main、Hesse、ドイツ、60590
- Oruka Therapeutics Investigative Site
-
-
Lower Saxony
-
Bad Bentheim、Lower Saxony、ドイツ、48455
- Oruka Therapeutics Investigative Site
-
-
Schleswig-Holstein
-
Kiel、Schleswig-Holstein、ドイツ、24105
- Oruka Therapeutics Investigative Site
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
-
Participants ≥ 18 years of age
-
Have a diagnosis of plaque psoriasis for > 6 months
-
Have moderate-to-severe chronic plaque psoriasis defined as:
- BSA ≥ 10%, and
- PASI ≥ 12, and
- IGA score of ≥ 3 on a 5-point scale
-
Candidate for systemic therapy or phototherapy
-
Women of childbearing potential must have a negative pregnancy test.
Exclusion Criteria:
- Nonplaque forms of psoriasis (including guttate, erythrodermic, or pustular) or drug-induced psoriasis
- Significant history or clinical manifestation of any metabolic, other dermatological, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, respiratory, endocrine, or psychiatric disorder, or any infectious disease
- History of malignancy, except for non-melanoma skin cancer or cancer curatively treated ≥ 5 years, without evidence of recurrence
- A known hypersensitivity to any components of the ORKA-001 drug product
- Women who are breastfeeding or plan to breastfeed during the study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:ダブル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:(Induction Period - Arm 1) ORKA-001
Participants will receive 37.5 mg ORKA-001 per protocol Induction regimen. |
ORKA-001 administered by subcutaneous (SC) injection |
|
実験的:(Induction Period - Arm 2) ORKA-001
Participants will receive 300 mg ORKA-001 per protocol Induction regimen. |
ORKA-001 administered by subcutaneous (SC) injection |
|
実験的:(Induction Period - Arm 3) ORKA-001
Participants will receive 600 mg ORKA-001 per protocol Induction regimen. |
ORKA-001 administered by subcutaneous (SC) injection |
|
プラセボコンパレーター:(Induction Period - Arm 4) Placebo
Participants will receive Placebo per protocol Induction regimen. |
Placebo administered by subcutaneous (SC) injection |
|
実験的:(Maintenance Period - Arm 1) ORKA-001
Participants will receive 300 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response. |
ORKA-001 administered by subcutaneous (SC) injection |
|
実験的:(Maintenance Period - Arm 2) ORKA-001
Participants will receive 600 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response. |
ORKA-001 administered by subcutaneous (SC) injection |
|
プラセボコンパレーター:(Maintenance Period - Arm 3) Placebo
Participants will receive Placebo per protocol Maintenance regimen, based on protocol defined response. |
Placebo administered by subcutaneous (SC) injection |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16
時間枠:Week 16
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 16
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of Participants Who Achieve an IGA = 0 (Clear) at Week 16
時間枠:Week 16
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
Proportion of Participants Achieving 90% Reduction in PASI Score at Week 16
時間枠:Week 16
|
Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 16
|
|
Proportion of Participants Who Achieve an IGA = 0 (Clear) or 1 (Almost Clear) at Week 16
時間枠:Week 16
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 16
|
|
Proportion of Participants Maintaining 100% Reduction in PASI Score at Week 100
時間枠:Week 100
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 100
|
|
Proportion of Participants Maintaining an IGA = 0 (Clear) at Week 100
時間枠:Week 100
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 100
|
|
Proportion of Participants Maintaining 90% Reduction in PASI Score at Week 100
時間枠:Week 100
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 100
|
|
Proportion of Participants Maintaining an IGA = 0 (Clear) or 1 (Almost Clear) at Week 100
時間枠:Week 100
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Week 100
|
|
Proportion of Participants Maintaining 75% Reduction in PASI Score at Week 100
時間枠:Week 100
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Week 100
|
|
Incidence of Treatment-emergent Adverse Events (TEAEs) and TEAEs of Special Interest (TEAESIs)
時間枠:Day 1 through Week 100
|
Incidence of treatment adverse events, treatment adverse events of special interest, and clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms |
Day 1 through Week 100
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。